Holen Sie sich die Stockscreener-App
53.76
3.90%
2.02
Handel nachbörslich:
53.76
Schlusskurs vom Vortag:
$51.74
Offen:
$52.25
24-Stunden-Volumen:
357.40K
Relative Volume:
0.53
Marktkapitalisierung:
$2.06B
Einnahmen:
$17.39M
Nettoeinkommen (Verlust:
$-135.89M
KGV:
-11.59
EPS:
-4.64
Netto-Cashflow:
$-123.00M
1W Leistung:
+10.21%
1M Leistung:
-2.91%
6M Leistung:
+121.33%
1J Leistung:
+97.36%
1-Tages-Spanne:
$51.84
$54.53
1-Wochen-Bereich:
$48.20
$54.53
52-Wochen-Spanne:
$20.08
$57.14
Tarsus Pharmaceuticals Inc Stock (TARS) Company Profile
Firmenname
Tarsus Pharmaceuticals Inc
Sektor
Branche
Telefon
(949) 409-9820
Adresse
15440 LAGUNA CANYON ROAD, IRVINE
Vergleichen Sie TARS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TARS
Tarsus Pharmaceuticals Inc
|
53.76 | 2.06B | 17.39M | -135.89M | -123.00M | -4.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Tarsus Pharmaceuticals Inc Stock (TARS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-11-20 | Eingeleitet | Goldman | Neutral |
| 2023-07-18 | Eingeleitet | William Blair | Outperform |
| 2023-05-18 | Eingeleitet | Guggenheim | Buy |
| 2022-08-01 | Eingeleitet | Barclays | Overweight |
| 2021-12-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-11-23 | Eingeleitet | Oppenheimer | Outperform |
| 2020-11-10 | Eingeleitet | BofA Securities | Buy |
| 2020-11-10 | Eingeleitet | Jefferies | Buy |
| 2020-11-10 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2020-11-10 | Eingeleitet | Raymond James | Strong Buy |
Alle ansehen
Tarsus Pharmaceuticals Inc Aktie (TARS) Neueste Nachrichten
Tarsus to Participate in Upcoming Investor Conferences - GlobeNewswire
Exclusive Access: Tarsus Pharma's Double-Header at Elite Healthcare Investment Forums - StockTitan
Tarsus to Participate in Upcoming Investor Conferences - GlobeNewswire Inc.
How To Trade (TARS) - Stock Traders Daily
Tarsus Pharmaceuticals (NASDAQ:TARS) Given New $62.00 Price Target at Barclays - Defense World
Tarsus Pharmaceuticals (NASDAQ:TARS) Trading Up 9% After Analyst Upgrade - Defense World
Tarsus Pharmaceuticals (NASDAQ:TARS) Trading 9% Higher After Analyst Upgrade - MarketBeat
A Glimpse Into The Expert Outlook On Tarsus Pharmaceuticals Through 4 Analysts - Benzinga
Tarsus Pharmaceuticals (NASDAQ:TARS) Price Target Raised to $62.00 at Barclays - MarketBeat
Oppenheimer lifts Tarsus stock target, impressed by execution and ocular rosacea potential - MSN
Tarsus Pharmaceuticals Inc (NASDAQ: TARS): An Enticing Stock To Watch - Stocks Register
Midday Stock Roundup: Virgin Galactic down 2.3% and 87% YoY - Orange County Business Journal
Tarsus: Promising Investment, But Timing Is The Key (NASDAQ:TARS) - Seeking Alpha
Oppenheimer Increases Tarsus Pharmaceuticals (NASDAQ:TARS) Price Target to $72.00 - MarketBeat
First Week of TARS March 21st Options Trading - Nasdaq
Tarsus PharmaceuticalEye Care Therapeutics - MSN
Is Tarsus Pharmaceuticals (TARS) Among Billionaire Joseph Edelman’s Long-Term Stock Picks? - Insider Monkey
Billionaire Joseph Edelman’s Top 10 Long-Term Stock Picks - Insider Monkey
Tarsus Pharmaceuticals reshuffles board, appoints new committee chair By Investing.com - Investing.com South Africa
Tarsus Pharmaceuticals reshuffles board, appoints new committee chair - MSN
Grant GrossMendelsohn LLC Sells 14,331 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - MarketBeat
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives $54.20 Average Target Price from Analysts - MarketBeat
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Tarsus Pharmaceuticals (NASDAQ:TARS) Publishes Corporate Presentation – Enhances Stakeholder InsightOn January 13, 2025, Tarsus Pharmaceuticals, Inc. shared its corporate presentation on its website’s Investor & News section, as detailed in the lates - Defense World
Tarsus Pharmaceuticals, Inc Announces Board and Committee Changes -January 17, 2025 at 05:09 pm EST - Marketscreener.com
Assenagon Asset Management S.A. Buys 5,565 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - MarketBeat
Down -9.11% in 4 Weeks, Here's Why Tarsus Pharmaceuticals (TARS) Looks Ripe for a Turnaround - MSN
Tarsus Pharmaceuticals (NASDAQ:TARS) Shares Down 6.3%Time to Sell? - MarketBeat
Tarsus Pharmaceuticals is Now Oversold (TARS) - Nasdaq
Tarsus CEO Bobby Azamian: Clearing Crusty Eyelids with Xdemvy - Orange County Business Journal
Tarsus Pharmaceuticals (NASDAQ:TARS) Shares Gap DownTime to Sell? - MarketBeat
Tarsus Provides 2025 Update: Accelerating the Launch of XDEMVY - WICZ
Tarsus Provides 2025 Update: Accelerating the Launch of - GlobeNewswire
Tarsus' XDEMVY Eye Treatment Hits $113M Sales, Plans New Rosacea Drug Development - StockTitan
Analysts Expect Breakeven For Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Before Long - Simply Wall St
JPMorgan Chase & Co. Has $14.48 Million Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Defense World
JPMorgan Chase & Co. Buys 420,057 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - MarketBeat
Strength Seen in Novavax (NVAX): Can Its 10.9% Jump Turn into More Strength? - Yahoo Finance
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Bought by Franklin Resources Inc. - Defense World
Tarsus Pharmaceuticals stock soars to 52-week high of $56.84 By Investing.com - Investing.com Australia
Tarsus Pharmaceuticals (NASDAQ:TARS) Sets New 12-Month HighHere's What Happened - MarketBeat
Tarsus Pharmaceuticals stock soars to 52-week high of $56.84 - Investing.com
How Tarsus Pharmaceuticals' Unique Inspiration Is Driving A Triple-Digit Run - MSN
Geode Capital Management LLC Increases Stock Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Defense World
Geode Capital Management LLC Purchases 62,555 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - MarketBeat
Finanzdaten der Tarsus Pharmaceuticals Inc-Aktie (TARS)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.95%
2.39%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):